VANCOUVER, March 9, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce that it is introducing the cannabis industry's most comprehensive product testing disclosure process. Today, the Company completed the first step in a two-step process that will provide Aurora clients and the general public with access to a simplified Certificate of Analysis (CoA) for every cannabis product available for sale on the Company's menu. The purpose of the new protocol is to provide clients with secure knowledge that every Aurora product available for purchase has been certified by an independent third-party laboratory as having passed testing for the widest possible range of potential contaminants.
The new system, developed in partnership with Anandia Labs Inc. ("Anandia"), Canada's foremost cannabis genetics and testing laboratory, will provide a certification link for each product featured on Aurora's menu, both through the Company's website and through its one-of-a-kind mobile application. Clicking the link will take clients to a product-specific webpage, providing a simplified CoA indicating that the product in question has been analyzed with high accuracy for potency, and passed Anandia's rigorous testing procedures for the presence of contaminants. These important enhancements will be implemented in two steps. The first step, now complete, added these certifications to the Company's website www.auroramj.com. The second step, to be completed soon, will update Aurora's online shop to place a certification link beside the image of each product for sale.
"This initiative further extends Aurora's best-in-class Quality Assurance and testing protocols, and gives our clients additional certainty regarding the purity and safety of the cannabis we produce and sell," said Terry Booth, CEO. "From the founding of our Company, we have established and emphasized a strict culture of regulatory compliance. We have never used pesticides in our production, yet we have always tested all the products we sell for the presence of pesticides and other potential contaminants. It is imperative that patients have confidence in the safety of the products they consume, and in the integrity of the medical cannabis system. We believe our testing disclosure process will raise the bar for the entire sector, and offer a model for other companies to follow."
Aurora has used independent laboratories to test every lot of product ever sold to clients for microbial contamination, as well as any potential contamination by heavy metals and pesticides. In October, 2016, the Company enhanced its procedures further by shifting its testing to Anandia, which is able to test cannabis for the presence of the broadest array of substances of any independent commercial laboratory in Canada. Since that time, Anandia has tested and passed 45 lots of Aurora products.
"Aurora's initiative to provide access to quality control test results will help their clients select the appropriate medication and give them peace of mind that it does not contain pesticides or other contaminants," said Dr. Jonathan Page, President and CEO of Anandia Labs. "Our industry leading testing protocols analyze for the presence of 51 pesticides and plant growth regulators, as well as other contaminants such as bacteria and heavy metals. We fully support Aurora in their efforts to bring a new level of transparency to the medical cannabis industry."
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport. The Aurora Sky project has secured advanced technology from the most renowned design and construction suppliers in the Netherlands. Aurora's common shares trade on the TSX-V under the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the Proposal will be completed on the terms or within the timeframe contemplated in this news release or at all. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc.